Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a

The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, ran...

Full description

Bibliographic Details
Main Authors: Rania M. El-Lababidi, Mohamad Mooty, Maria-Fernanda Bonilla, Nouran M. Salem
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:IDCases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2214250920301451
id doaj-ba530b11c12e41e2828cb01c42c810b1
record_format Article
spelling doaj-ba530b11c12e41e2828cb01c42c810b12021-07-02T19:46:19ZengElsevierIDCases2214-25092020-01-0121e00837Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2aRania M. El-Lababidi0Mohamad Mooty1Maria-Fernanda Bonilla2Nouran M. Salem3Department of Pharmacy Services, Cleveland Clinic Abu Dhabi, Al Maryah Island, p.o. box 112412, Abu Dhabi, United Arab Emirates; Corresponding author.Department of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, Abu Dhabi, p.o. box 112412, United Arab EmiratesDepartment of Infectious Diseases, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab EmiratesDepartment of Pharmacy Services, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab EmiratesThe outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.http://www.sciencedirect.com/science/article/pii/S2214250920301451Coronavirus disease 2019Pegylated interferon alfa 2aInterferonsSARS-CoV-2
collection DOAJ
language English
format Article
sources DOAJ
author Rania M. El-Lababidi
Mohamad Mooty
Maria-Fernanda Bonilla
Nouran M. Salem
spellingShingle Rania M. El-Lababidi
Mohamad Mooty
Maria-Fernanda Bonilla
Nouran M. Salem
Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
IDCases
Coronavirus disease 2019
Pegylated interferon alfa 2a
Interferons
SARS-CoV-2
author_facet Rania M. El-Lababidi
Mohamad Mooty
Maria-Fernanda Bonilla
Nouran M. Salem
author_sort Rania M. El-Lababidi
title Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_short Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_full Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_fullStr Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_full_unstemmed Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
title_sort treatment of severe pneumonia due to covid-19 with peginterferon alfa 2a
publisher Elsevier
series IDCases
issn 2214-2509
publishDate 2020-01-01
description The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.
topic Coronavirus disease 2019
Pegylated interferon alfa 2a
Interferons
SARS-CoV-2
url http://www.sciencedirect.com/science/article/pii/S2214250920301451
work_keys_str_mv AT raniamellababidi treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a
AT mohamadmooty treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a
AT mariafernandabonilla treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a
AT nouranmsalem treatmentofseverepneumoniaduetocovid19withpeginterferonalfa2a
_version_ 1721323606720380928